RESUMEN
A 10-year-old, neutered male, Golden Retriever dog presented for surgical correction of a descemetocele. Acepromazine (0.02 mg/kg) and methadone (0.5 mg/kg) were administered intramuscularly for sedation, propofol (2 mg/kg) and midazolam (0.2 mg/kg) were administered intravenously for anaesthetic induction and isoflurane in oxygen was utilised for anaesthetic maintenance. Rocuronium (0.5 mg/kg), a neuromuscular blocking agent, was administered intravenously to facilitate central positioning of the eye for surgery. Within 10 min of rocuronium administration, the dog became tachycardic and hypotensive. Hemodynamic aberrations did not resolve with initial interventions but were successfully mitigated with the administration of diphenhydramine (0.8 mg/kg) intravenously. The dog remained stable throughout the remainder of the procedure and experienced a smooth and uneventful recovery. While it is difficult to confirm that the hemodynamic changes observed in this clinical case resulted solely from administration of rocuronium, the observance of the cardiovascular changes, timing of events and response to therapy suggest that rocuronium elicited a histamine response that was successfully treated with diphenhydramine.
Asunto(s)
Fármacos Neuromusculares no Despolarizantes , Rocuronio , Animales , Rocuronio/administración & dosificación , Perros , Masculino , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Hemodinámica/efectos de los fármacos , Androstanoles/administración & dosificación , Enfermedades de los Perros/cirugía , Difenhidramina/administración & dosificaciónRESUMEN
INTRODUCTION: The effect of neuromuscular blocking agents may be reversed by administration of neostigmine, when two twitches are present using train-of-four (TOF) stimulation. However, in elderly patients, limited data are available about when to administer neostigmine. We hypothesised that time to two twitches after TOF (TOF-2) was shorter after rocuronium 0.6 mg/kg than after rocuronium 0.9 mg/kg. Also, we hypothesised that time to TOF-2 would be shorter after rocuronium 0.3 mg/kg than after rocuronium 0.6 mg/kg. METHODS: This was a secondary analysis of 50 elderly patients > 80 years; 16 patients received rocuronium 0.6 mg/kg, another 16 patients received rocuronium 0.9 mg/kg; and, finally, 18 patients received rocuronium 0.3 mg/kg. Patients received total intravenous anaesthesia, and neuromuscular block was monitored with acceleromyography. RESULTS: Time to TOF-2 was shorter after rocuronium 0.6 mg/kg than after rocuronium 0.9 mg/kg: 37 min. versus 59 min. (difference: 22 min. (95% confidence intervals (CI): 10 to 33 min.), p = 0.0007). Time to TOF-2 after rocuronium 0.3 mg/kg was shorter than after rocuronium 0.6 mg/kg: 19 min. versus 37 min. (difference: 18 min. (95% CI: 11 to 25 min.), p = 0.00006). However, only 33% of the patients receiving 0.3 mg/kg obtained full effect i.e. TOF-0. CONCLUSION: Time to TOF-2 was shorter after rocuronium 0.6 mg/kg than after 0.9 mg/kg and shorter after rocuronium 0.3 mg/kg than after 0.6 mg/kg. FUNDING: This work was supported by departmental sources. TRIAL REGISTRATION: This study was a secondary analysis of two clinical trials. CLINICALTRIALS: gov (NCT04512313), (NCT03857750).
Asunto(s)
Periodo de Recuperación de la Anestesia , Neostigmina , Bloqueo Neuromuscular , Fármacos Neuromusculares no Despolarizantes , Rocuronio , Humanos , Rocuronio/administración & dosificación , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Anciano de 80 o más Años , Femenino , Masculino , Bloqueo Neuromuscular/métodos , Neostigmina/administración & dosificación , Factores de Tiempo , Monitoreo Neuromuscular/métodos , Relación Dosis-Respuesta a Droga , Androstanoles/administración & dosificaciónRESUMEN
BACKGROUND: The number of trials investigating the effects of deep neuromuscular blockade (NMB) on surgical conditions and patient outcomes is steadily increasing. Consensus on which surgical procedures benefit from deep NMB (a posttetanic count [PTC] of 1 to 2) and how to implement it has not been reached. The European Society of Anaesthesiology and Intensive Care does not advise routine application but recommends use of deep NMB to improve surgical conditions on indication. This study investigates the optimal dosing strategy to reach and maintain adequate deep NMB during total intravenous anesthesia. METHODS: Data from three trials investigating deep NMB during laparoscopic surgery with total intravenous anesthesia (n = 424) were pooled to analyze the required rocuronium dose, when to start continuous infusion, and how to adjust. The resulting algorithm was validated (n = 32) and compared to the success rate in ongoing studies in which the algorithm was not used (n = 180). RESULTS: The mean rocuronium dose based on actual bodyweight for PTC 1 to 2 was (mean ± SD) 1.0 ± 0.27 mg · kg-1 ·h-1 in the trials, in which mean duration of surgery was 116 min. An induction dose of 0.6 mg ·kg-1 led to a PTC of 1 to 5 in a quarter of patients after a mean of 11 min. The remaining patients were equally divided over too shallow (additional bolus and direct start of continuous infusion) or too deep; a 15-min wait after PTC of 0 for return of PTC to 1 or higher. Using the proposed algorithm, a mean 76% of all 5-min measurements throughout surgery were on target PTC 1 to 2 in the validation cohort. The algorithm performed significantly better than anesthesiology residents without the algorithm, even after a learning curve from 0 to 20 patients (42% on target, P ≤ 0.001, Cohen's d = 1.4 [95% CI, 0.9 to 1.8]) to 81 to 100 patients (61% on target, P ≤ 0.05, Cohen's d = 0.7 [95% CI, 0.1 to 1.2]). CONCLUSIONS: This study proposes a dosing algorithm for deep NMB with rocuronium in patients receiving total intravenous anesthesia.
Asunto(s)
Algoritmos , Anestesia Intravenosa , Bloqueo Neuromuscular , Fármacos Neuromusculares no Despolarizantes , Rocuronio , Humanos , Rocuronio/administración & dosificación , Bloqueo Neuromuscular/métodos , Masculino , Persona de Mediana Edad , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Femenino , Anestesia Intravenosa/métodos , Adulto , Relación Dosis-Respuesta a Droga , Anciano , Laparoscopía/métodos , Androstanoles/administración & dosificaciónRESUMEN
Background: There have been few studies comparing the effects of high- and low-dose rocuronium during cesarean section by directly measuring the concentration. Therefore, we conducted a study to examine the blood concentrations and clinical effects of both doses of rocuronium on mothers and fetuses. Methods: Eighteen patients were randomly assigned to two groups: C Group (0.6 mg/kg), and H Group, (1.0 mg/kg). The primary outcome was the comparison of umbilical vein rocuronium concentration between two groups. We assessed ease of intubation, time from rocuronium administration to some TOF points, post-anesthesia care unit (PACU) stay time, infused remifentanil dose, maternal rocuronium concentration, and Apgar scores. Results: No differences were observed in demographic data, ease of intubation, PACU stay time, 1 min Apgar scores, umbilical venous blood gas analysis between both groups. However, the time from rocuronium administration to T3 disappearance was shorter (p=0.009) and time to T1 and T2 reappearance were longer (p=0.003, p=0.009) in H group than that in C group. The administered remifentanil dose (p=0.042) was lower in the H group than in the C group. Rocuronium concentrations in the umbilical vein (p=0.004) and maternal vein before cord clamping (p=0.002) and at discharge (p<0.001) were also found to be higher in the H group than in the C group. Conclusions: We observed no prolongation of PACU stay, and no differences in Apgar scores in H group compared to C group. It suggests that 1.0 mg/kg of rocuronium has no negative effects on the fetus and mother in cesarean section.
Asunto(s)
Anestesia General , Cesárea , Fármacos Neuromusculares no Despolarizantes , Rocuronio , Humanos , Rocuronio/administración & dosificación , Cesárea/métodos , Femenino , Embarazo , Anestesia General/métodos , Adulto , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Remifentanilo/administración & dosificación , Puntaje de Apgar , Relación Dosis-Respuesta a Droga , Androstanoles/administración & dosificación , Androstanoles/sangreRESUMEN
OBJECTIVE: In our study, we aimed to compare the effect of standard rapid sequence intubation protocol and the application of rocuronium priming technique on the procedure time and hemodynamic profile. METHODS: Patients who applied to the emergency department and needed rapid sequence intubation were included in our study, which we conducted with a randomized controlled design. Randomization in the study was made according to the order of arrival of the cases. Rapid sequence intubation was performed in the standard group. In the priming group, 10% of the rocuronium dose was administered approximately 3 min before the induction agent. Intubation time, amount of drug used, vital signs, and end-tidal CO2 level before and after intubation used to confirm intubation were recorded. RESULTS: A total of 52 patients were included in the study, of which 26 patients were included in the standard group and 26 patients in the priming group. While intubation time was 121.2±21.9 s in the standard group, it was calculated as 68.4±11.6 s in the priming group (p<0.001). While the mean arterial pressure was 58.3±26.6 mmHg in the standard group after intubation, it was 80.6±21.1 mmHg in the priming group (p=0.002). CONCLUSION: It was observed that priming with rocuronium shortened the intubation time and preserved the hemodynamic profile better. CLINICAL TRIAL REGISTRATION NUMBER: NCT05343702.
Asunto(s)
Androstanoles , Servicio de Urgencia en Hospital , Intubación Intratraqueal , Fármacos Neuromusculares no Despolarizantes , Intubación e Inducción de Secuencia Rápida , Rocuronio , Humanos , Rocuronio/administración & dosificación , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Femenino , Masculino , Intubación e Inducción de Secuencia Rápida/métodos , Adulto , Persona de Mediana Edad , Androstanoles/administración & dosificación , Factores de Tiempo , Intubación Intratraqueal/métodos , Hemodinámica/efectos de los fármacosAsunto(s)
Accidentes de Trabajo , Androstanoles/administración & dosificación , Fármacos Neuromusculares no Despolarizantes/efectos adversos , Rocuronio/efectos adversos , Adulto , Androstanoles/efectos adversos , Ojo , Femenino , Humanos , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Rocuronio/administración & dosificaciónRESUMEN
BACKGROUND: We recently showed that a neurosteroid analogue, (3ß,5ß,17ß)-3-hydroxyandrostane-17-carbonitrile (3ß-OH), induced hypnosis in rats. The aim of the present study was to evaluate the hypnotic and anaesthetic potential of 3ß-OH further using electroencephalography. METHODS: We used behavioural assessment and cortical electroencephalogram (EEG) spectral power analysis to examine hypnotic and anaesthetic effects of 3ß-OH (30 and 60 mg kg-1) administered intraperitoneally or intravenously to young adult male and female rats. RESULTS: We found dose-dependent sex differences in 3ß-OH-induced hypnosis and EEG changes. Both male and female rats responded similarly to i.p. 3ß-OH 30 mg kg-1. However, at the higher dose (60 mg kg-1, i.p.), female rats had two-fold longer duration of spontaneous immobility than male rats (203.4 [61.6] min vs 101.3 [32.1] min), and their EEG was suppressed in the low-frequency range (2-6 Hz), in contrast to male rats. Although a sex-dependent hypnotic effect was not confirmed after 30 mg kg-1 i.v., female rats appeared more sensitive to 3ß-OH with relatively small changes within delta (1-4 Hz) and alpha (8-13 Hz) bands. Finally, 3ß-OH had a rapid onset of action and potent hypnotic/anaesthetic effect after 60 mg kg-1 i.v. in rats of both sexes; however, all female rats and only half of the male rats reached burst suppression, an EEG pattern usually associated with profound inhibition of thalamocortical networks. CONCLUSIONS: Based on its behavioural effects and EEG signature, 3ß-OH is a potent hypnotic in rats, with female rats being more sensitive than male rats.
Asunto(s)
Androstanoles/farmacología , Ondas Encefálicas/efectos de los fármacos , Corteza Cerebral/efectos de los fármacos , Electrocorticografía , Pérdida de Tono Postural/efectos de los fármacos , Neuroesteroides/farmacología , Nitrilos/farmacología , Androstanoles/administración & dosificación , Animales , Corteza Cerebral/fisiopatología , Relación Dosis-Respuesta a Droga , Femenino , Inyecciones Intraperitoneales , Inyecciones Intravenosas , Masculino , Neuroesteroides/administración & dosificación , Nitrilos/administración & dosificación , Ratas Sprague-Dawley , Factores Sexuales , Factores de TiempoRESUMEN
Objective: To investigate the efficacy and safety of sugammadex for antagonistic neuromuscular block in patients with radical resection of lung cancer under thoracoscope. Methods: One hundred patients undergoing radical resection of lung cancer under thoracoscope in Affiliated Cancer Hospital of Zhengzhou University from March to September in 2019, were randomly divided into control group (group C) and sugammadex group (group S). All patients were anaesthetized (induced and maintained) with intravenous target-controlled infusion of propofol and remifentanil, and intermittent intravenous injection of the neuromuscular block of rocuronium. During the operation, the bispectral index (BIS) was used to monitor the depth of anesthesia, and the neuromuscular block was assessed with TOF. Single-lung mechanical ventilation and double-lumen endotracheal intubation were carried out, and patient-controlled analgesia after operation were enforced. Patients in group C received neostigmine (2 mg) combined with atropine (0.5-1.0 mg) after thoracic closure, while patients in group S received sugammadex (2 mg/kg) at TOF count (≥2) after thoracic closure, and then double-lumen endotracheal tubes were extubated according to extubation indications. At these time points: T(0) (immediate before anesthesia induction), T(1) (immediate before tracheal intubation), T(2) (immediately after thoracic closure), T(3) (1 h after operation), T(4) (6 h after operation), T(5) (24 h after operation), T(6)(48 h after operation), the heart rate(HR) and mean arterial pressure (MAP) were recorded, QT interval (V3 ECG) were measured and calculated, indicators of liver function [alanine transaminase (ALT), aspartate transaminase(AST)], renal function [blood urea nitrogen (BUN), creatinine (Cre)] and clotting function [thrombin time (TT), prothrombin time (PT), activated partial thromboplastin time (APTT) and fibrinogen (FIB)] were detected. The duration of operation, postoperative conditions within 48 hours after operation(the time of tracheal tube extubation, respiratory suppression/dysfunction, allergy, nausea and vomiting, itching of skin, abnormal sensation), pathological types and the postoperative hospital stay were recorded. Results: There were no significant differences of the age, sex ratio, body mass index (BMI), American Society of Anesthesiologists (ASA) grading ratio, duration of operation, pathological types and the postoperative hospital stay, HR, MAP and QT interval between two groups (all P>0.05). There were no remarkable differences of the levels of serum histamine, ALT, AST, BUN, Cre, TT, PT, APTT and FIB before and after administration of neuromuscular blockade antagonists (neostigmine or Sugammadex) in the same group patients (all P>0.05), also no significant differences between group C and group S at the same time points (all P>0.05). Average time of tracheal tube extubation in group S [(3.7±1.3) min] was sharply shorter than that in group C [(14.5±4.4) min, t=2.266, P<0.05)]. There were no patients with allergy, skin itching, sensory abnormality in these two groups. There were no significant difference of the incidence of postoperative nausea and vomiting between these two groups. There were 5 patients with respiratory depression in group C and no respiratory depression patient in group S, the difference was statistically significant between these two groups (χ(2)=5.263, P<0.05). Conclusion: Sugammadex is effective for antagonizing the neuromuscular blockade of rocuronium in patients with radical resection of lung cancer under thoracoscope, and can shorten the time of tracheal tube extubation after surgery.
Asunto(s)
Neoplasias Pulmonares/cirugía , Bloqueo Neuromuscular/métodos , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Sugammadex/administración & dosificación , gamma-Ciclodextrinas , Androstanoles/administración & dosificación , Androstanoles/antagonistas & inhibidores , Inhibidores de la Colinesterasa , Humanos , Neoplasias Pulmonares/patología , Neostigmina/administración & dosificación , Fármacos Neuromusculares no Despolarizantes/efectos adversos , Sugammadex/efectos adversos , ToracoscopiosRESUMEN
Hypobaric hypoxia (HH) exposure can cause serious brain injury as well as life-threatening cerebral edema in severe cases. Previous studies on the mechanisms of HH-induced brain injury have been conducted primarily using non-primate animal models that are genetically distant to humans, thus hindering the development of disease treatment. Here, we report that cynomolgus monkeys ( Macacafascicularis) exposed to acute HH developed human-like HH syndrome involving severe brain injury and abnormal behavior. Transcriptome profiling of white blood cells and brain tissue from monkeys exposed to increasing altitude revealed the central role of the HIF-1 and other novel signaling pathways, such as the vitamin D receptor (VDR) signaling pathway, in co-regulating HH-induced inflammation processes. We also observed profound transcriptomic alterations in brains after exposure to acute HH, including the activation of angiogenesis and impairment of aerobic respiration and protein folding processes, which likely underlie the pathological effects of HH-induced brain injury. Administration of progesterone (PROG) and steroid neuroprotectant 5α-androst-3ß,5,6ß-triol (TRIOL) significantly attenuated brain injuries and rescued the transcriptomic changes induced by acute HH. Functional investigation of the affected genes suggested that these two neuroprotectants protect the brain by targeting different pathways, with PROG enhancing erythropoiesis and TRIOL suppressing glutamate-induced excitotoxicity. Thus, this study advances our understanding of the pathology induced by acute HH and provides potential compounds for the development of neuroprotectant drugs for therapeutic treatment.
Asunto(s)
Androstanoles/farmacología , Hipoxia/veterinaria , Macaca fascicularis , Enfermedades de los Monos/prevención & control , Progesterona/farmacología , Transcriptoma , Androstanoles/administración & dosificación , Animales , Encefalopatías/prevención & control , Encefalopatías/veterinaria , Calcio/metabolismo , Regulación de la Expresión Génica , Hipoxia/patología , Leucocitos/metabolismo , Masculino , Fármacos Neuroprotectores/farmacología , Presión , Progesterona/administración & dosificaciónRESUMEN
Quantitative neuromuscular block (NMB) assessment is an internationally recognised necessity in anesthesia care whenever neuromuscular blocking agents are administered. Despite this, the incidence of residual neuromuscular block and its associated major respiratory morbidity and mortality remain unacceptably high considering its preventable nature. Recent surveys show that quantitative NMB assessment is not consistently employed by anesthesiologists. Availability, price and practical concerns are some of the factors determining this phenomenon. Clinically assess and validate an Android cell phone application conceived specifically for NMB Monitoring in the anesthesia setting. Twenty-two adult ASA I to III patients scheduled to undergo elective surgical procedures under general anaesthesia requiring administration of a neuromuscular blocking agent were included. After anaesthesia induction, the grade of neuromuscular block was assessed at multiple independent time-points by paired comparison of the train of four (TOF) Ratios obtained by a Stimpod™ accelerometer and the currently developed application. Accelerometric measurements were made at the patient's hand after retrograde supramaximal stimulation of the ipsilateral ulnar nerve. TOF-ratios were subjected to bias analysis with 0.001 as the a priori established clinical significance cut-off. The difference between the two methods averaged 0.0004 (95% limits of agreement: ± 0.12), with 83.3% of the differences being under 0.05. This average inter-method difference was not significantly different than the a priori hypothesized difference cut-off of 0.001 (p = 0.78). Lin's concordance correlation coefficient and Pearson's correlation were both of 0.98. The custom developed Android application proved accurate for diagnosis of residual neuromuscular block.
Asunto(s)
Aplicaciones Móviles , Monitoreo Intraoperatorio/instrumentación , Bloqueo Neuromuscular/métodos , Monitoreo Neuromuscular/métodos , Teléfono Inteligente , Acelerometría , Androstanoles/administración & dosificación , Anestesia , Anestesia General , Anestesiología , Retraso en el Despertar Posanestésico/diagnóstico , Femenino , Humanos , Estudios Longitudinales , Masculino , Monitoreo Intraoperatorio/métodos , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Estudios Prospectivos , Reproducibilidad de los Resultados , Interfaz Usuario-ComputadorRESUMEN
There is a growing body of literature documenting the use of deep neuromuscular block (NMB) during surgery. Traditional definitions of depth of NMB rely on train-of-four assessment, which can be less reliable in retrospective studies. The goal of our study was to investigate the real-world practice pattern of dosing of neuromuscular blocking agents (NMBA), utilizing the amount of NMBA used during the course of a case, adjusted for patient weight and case duration, as a surrogate measure of depth of NMB. We also aimed to identify case factors associated with larger NMBA doses. In this retrospective observational analysis of our anesthesia information management system, we analyzed all general endotracheal anesthesia cases from 2012 to 2015 in which an intermediate-acting NMBA was used. Cases using a long-acting NMBA or only succinylcholine were excluded. The expected duration of the case was calculated based on the cumulative dose of NMB used, normalized to the patient's ideal body weight and the ED95 of the drug. If the expected duration of the case was greater than the actual case duration documented in the case record, it was classified as higher dosing (HD). If the expected duration was equal to or less than the actual duration, it was considered predicted dosing (PD). Categorical comparisons between HD and PD groups were made for various patient, procedural, and provider factors. 72,684 cases were included in the final analysis, of which 46,358, or 64% of cases, used HD. Cases with patients who were morbidly obese, younger than 65 years, and who were lower ASA Physical Status classification (I or II) used more HD as opposed to PD. Cases that were non-open, used total intravenous anesthesia, emergent cases, or used non-rapid sequence anesthesia induction had higher rates of HD than their matched counterparts. All results were statistically significant. HD was more common in cases that documented train-of-four and used the reversal agent neostigmine. Approximately two-thirds of general endotracheal anesthesia cases using an intermediate-acting NMBA used HD. Cases with higher rates of HD may be those that are traditionally technically complex or emergent, would benefit from greater paralysis, or do not use adjunctive medications for muscle relaxation. Age greater than 65 years was shown to have lower rates of HD, likely due to provider awareness of age-related changes in pharmacokinetics and pharmacodynamics. Intraoperative monitoring and NMB antagonism with neostigmine were used more frequently with HD.
Asunto(s)
Monitoreo Intraoperatorio , Neostigmina/administración & dosificación , Bloqueo Neuromuscular , Bloqueantes Neuromusculares/administración & dosificación , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Androstanoles/administración & dosificación , Anestesia General , Atracurio/administración & dosificación , Atracurio/análogos & derivados , Índice de Masa Corporal , Registros Electrónicos de Salud , Femenino , Humanos , Masculino , Persona de Mediana Edad , Relajación Muscular , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Prevalencia , Estudios Retrospectivos , Rocuronio/administración & dosificación , Sugammadex/administración & dosificación , Bromuro de Vecuronio/administración & dosificación , Adulto JovenRESUMEN
BACKGROUND: The aim of this study was to investigate the clinical effectiveness of rocuronium in low doses on conditions during rapid tracheal intubation using video laryngoscope. METHODS: Ninety-eight patients undergoing otolaryngologic surgery were randomly divided into 2 groups: group L using 0.3âmg/kg of rocuronium intravenously (nâ=â49) and group C using 0.6âmg/kg of rocuronium (nâ=â49). Sixty seconds after rocuronium administration, tracheal intubation was performed using a video laryngoscope. The overall intubation condition was evaluated along with specific conditions, including laryngoscopy condition, vocal cord position, and intubation response. Intubation profiles, including Cormack-Lehane grade, 1st attempt success rate, and intubation time, were also evaluated. RESULTS: Overall intubation conditions showed a significant difference between group L and group C (Pâ=â.003). Although the incidence of vigorous response after tracheal intubation was higher in group L than in group C (Pâ=â.022), laryngoscopy condition and vocal cord position were similar between the 2 groups (Pâ=â.145 and .070, respectively). Intubation profiles showed no differences between the 2 groups. The frequency and amount of additional rocuronium administration during surgery were also similar. CONCLUSIONS: Low-dose rocuronium provided significantly worse overall intubation conditions compared to the conventional dose of rocuronium for rapid tracheal intubation. However, when using a video laryngoscope, it may provide clinically acceptable laryngeal muscle relaxation.
Asunto(s)
Androstanoles/administración & dosificación , Intubación Intratraqueal/métodos , Laringoscopía/métodos , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Cirugía Asistida por Video/métodos , Adulto , Método Doble Ciego , Femenino , Humanos , Intubación Intratraqueal/instrumentación , Músculos Laríngeos/efectos de los fármacos , Laringoscopios , Laringoscopía/instrumentación , Masculino , Persona de Mediana Edad , Rocuronio , Factores de Tiempo , Resultado del Tratamiento , Cirugía Asistida por Video/instrumentación , Pliegues Vocales/efectos de los fármacosRESUMEN
Recent data shows that a neuromuscular block (NMB) induced by administration of high doses of rocuronium improves surgical conditions in certain procedures. However, there are limited data on the effect such practices on postoperative outcomes. We performed a retrospective analysis to compare unplanned 30-day readmissions in patients that received high-dose versus low-dose rocuronium administration during general anesthesia for laparoscopic retroperitoneal surgery. This retrospective cohort study was performed in the Netherlands in an academic hospital where routine high-dose rocuronium NMB has been practiced since July 2015. Charts of patients receiving anesthesia between January 2014 and December 2016 were searched for surgical cases receiving high-dose rocuronium and matched with respect to procedure, age, sex and ASA classification to patients receiving low-dose rocuronium. The primary post-operative outcome was unplanned 30-day readmission rate. There were 130 patients in each cohort. Patients in the high- and low-dose rocuronium cohorts received 217 ± 49 versus 37 ± 5 mg rocuronium, respectively. In the high-dose rocuronium group neuromuscular activity was consistently monitored; matched patients were unreliably monitored. All patients receiving high-dose rocuronium were reversed with sugammadex, while just 33% of matched patients were reversed with sugammadex and 20% with neostigmine; the remaining patients were not reversed. Unplanned 30-day readmission rate was significantly lower in the high-dose compared to the low-dose rocuronium cohort (3.8% vs. 12.7%; p = 0.03; odds ratio = 0.33, 95% C.I. 0.12-0.95). This small retrospective study demonstrates a lower incidence of unplanned readmissions within 30-days following laparoscopic retroperitoneal surgery with high-dose relaxant anesthesia and sugammadex reversal in comparison to low-dose relaxant anesthesia. Further prospective studies are needed in larger samples to corroborate our findings and additionally assess the pharmacoeconomics of high-dose relaxant anesthesia taking into account the benefits (reduced readmissions) and harm (cost of relaxants and reversal agents) of such practice.
Asunto(s)
Androstanoles/administración & dosificación , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Laparoscopía , Masculino , Persona de Mediana Edad , Bloqueo Neuromuscular , Dolor Postoperatorio/tratamiento farmacológico , Readmisión del Paciente , Espacio Retroperitoneal/cirugía , Estudios Retrospectivos , RocuronioRESUMEN
This is a case of a 31-year-old Filipino man with chronic methamphetamine use disorder who developed tetanus from a necrotic skin graft over his left calcaneus, which was fractured after a motor vehicular accident. During the course of his illness, the patient's muscle spasms were unusually refractory to benzodiazepine, which is the first-line drug used in the management of muscle spasms. The muscle spasms were successfully controlled on the seventh day of illness with rocuronium at a dose of 10 µg/kg/min and midazolam at 0.30 mg/kg/hour. Both infusions were tapered off until the 23rd day of illness. The patient was discharged on the 30th day of illness, improved and stable.
Asunto(s)
Trastornos Relacionados con Anfetaminas/complicaciones , Androstanoles/administración & dosificación , Metanfetamina , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Espasmo/tratamiento farmacológico , Tétanos/complicaciones , Adulto , Anestésicos Intravenosos/administración & dosificación , Humanos , Infusiones Intravenosas , Masculino , Midazolam/administración & dosificación , Rocuronio , Trasplante de Piel/efectos adversos , Espasmo/etiología , Tétanos/tratamiento farmacológicoRESUMEN
Donor safety is the major concern in living donor liver transplantation, although hepatic resection may be associated with postoperative coagulopathy. Recently, the use of sugammadex has been gradually increased, but sugammadex is known to prolong prothrombin time (PT) and activated partial thromboplastin time (aPTT). We compared the postoperative coagulation profiles and outcomes of sugammadex versus pyridostigmine group in donors receiving living donor hepatectomy.Consecutive donor hepatectomy performed between September 2013 and August 2016 was retrospectively analyzed. For reversal of rocuronium-induced neuromuscular blockade, donors received sugammadex 4âmg/kg or pyridostigmine 0.25âmg/kg. The primary end-points were laboratory findings (PT, aPTT, hemoglobin, platelet count) and clinically evaluated postoperative bleeding (relaparotomy for bleeding, cumulative volume collected in drains). Secondary outcomes were anesthesia time, postoperative hospital day.Of 992 donors, 383 treated with sugammadex and 609 treated with pyridostigmine for the reversal of neuromuscular blockade. There were no significant differences between both groups for drop in hemoglobin and platelet, prolongation in PT, aPTT, and the amount of 24-h drain volume. Bleeding events within 24âh were reported in 2 (0.3%) for pyridostigmine group and 0 (0%) for sugammadex group (Pâ=â.262). Anesthesia time was significantly longer in pyridostigmine group than that in sugammadex group (438.8â±â71.4 vs. 421.3â±â62.3, Pâ<â.001). Postoperative hospital stay was significantly longer in pyridostigmine group than that in sugammadex group (Pâ=â.002).Sugammadex 4âmg/kg was not associated with increased bleeding tendency, but associated with reduced anesthesia time and hospital stay. Therefore, sugammadex may be safely used and will decrease morbidity in donor undergoing living-donor hepatectomy.
Asunto(s)
Trastornos de la Coagulación Sanguínea , Hepatectomía , Donadores Vivos , Complicaciones Posoperatorias , Bromuro de Piridostigmina , gamma-Ciclodextrinas , Adulto , Androstanoles/administración & dosificación , Androstanoles/efectos adversos , Periodo de Recuperación de la Anestesia , Coagulación Sanguínea/efectos de los fármacos , Trastornos de la Coagulación Sanguínea/sangre , Trastornos de la Coagulación Sanguínea/diagnóstico , Trastornos de la Coagulación Sanguínea/etiología , Trastornos de la Coagulación Sanguínea/prevención & control , Pruebas de Coagulación Sanguínea/métodos , Femenino , Hepatectomía/efectos adversos , Hepatectomía/métodos , Humanos , Trasplante de Hígado/métodos , Masculino , Fármacos Neuromusculares/administración & dosificación , Fármacos Neuromusculares/efectos adversos , Evaluación de Procesos y Resultados en Atención de Salud , Complicaciones Posoperatorias/sangre , Complicaciones Posoperatorias/diagnóstico , Complicaciones Posoperatorias/prevención & control , Bromuro de Piridostigmina/administración & dosificación , Bromuro de Piridostigmina/efectos adversos , Estudios Retrospectivos , Rocuronio , Sugammadex , gamma-Ciclodextrinas/administración & dosificación , gamma-Ciclodextrinas/efectos adversosRESUMEN
BACKGROUND: Combined rocuronium and cisatracurium have synergistic effects. We investigated whether reduced doses are effective during coadministration, by monitoring neuromuscular relaxation during surgery. METHODS: This randomized, controlled clinical trial was registered at http://clinicaltrials.gov (registration number NCT02495038). The participants were 81 patients scheduled for elective mastoidectomy and tympanoplasty. Participants were assigned to groups, including the intubating dose group (Group I, nâ=â27; combined ED95 rocuronium and ED95 cisatracurium), the small reduction group (Group S, nâ=â27; dose reduced by 10% of each ED95), or the large reduction group (Group L, nâ=â27; dose reduced by 20% of each ED95). Drugs were administered to patients and a timer was started using TOF-Watch monitoring. TOF (train-of-four) was monitored at the ulnar nerve, at a setting of 2âHz/12âs. We recorded the time to TOF ratioâ=â0 (onset), time to first TOF ratio >â25% (duration 25%), and TOF 25-75% (recovery index) under total intravenous anesthesia. One-way analysis of variance was used for statistical analyses (αâ=â0.05, ßâ=â0.2). RESULTS: There were no significant demographic differences between groups. Group L had a longer duration to onset (meanâ±âstandard deviation, 399.3â±â147.8âseconds) and shorter duration 25% (39.4â±â6.8âminutes) compared to Group I (212.8â±â56.0âs and 51.3â±â8.47âminutes, respectively) and Group S (230.7â±â60.6âs and 47.9â±â10.7âminutes, respectively). There were no other significant differences between groups. CONCLUSION: Our findings contribute to determining clinically effective combinations of rocuronium and cisatracurium, as well as to predicting the pharmacokinetic characteristics of the synergistic effects. We suggest that reducing doses of both drugs by approximately 10% of their respective ED95 values is sufficient to maintain neuromuscular relaxation during minor surgery.
Asunto(s)
Androstanoles/administración & dosificación , Atracurio/análogos & derivados , Mastoidectomía/métodos , Bloqueantes Neuromusculares/administración & dosificación , Timpanoplastia/métodos , Adulto , Anestesia General/métodos , Atracurio/administración & dosificación , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada , Procedimientos Quirúrgicos Electivos/métodos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Procedimientos Quirúrgicos Menores/métodos , Monitoreo Neuromuscular , Rocuronio , Factores de Tiempo , Nervio Cubital , Adulto JovenRESUMEN
We experienced a case of anaphylactic shock in a young asthmatic child immediately after administering rocuronium during the induction of anesthesia. Because urticaria did not develop immediately after ventilation difficulty, we diagnosed and responded to asthma, rather than to anaphylactic shock. Correct and rapid response to anaphylactic is extremely important.
Asunto(s)
Anafilaxia/inducido químicamente , Androstanoles/efectos adversos , Fármacos Neuromusculares no Despolarizantes/efectos adversos , Anafilaxia/diagnóstico , Anafilaxia/terapia , Androstanoles/administración & dosificación , Anestesia/métodos , Asma/complicaciones , Niño , Humanos , Masculino , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , RocuronioAsunto(s)
Androstanoles/administración & dosificación , Toma de Decisiones , Urgencias Médicas , Intubación Intratraqueal/métodos , Succinilcolina/administración & dosificación , Relación Dosis-Respuesta a Droga , Humanos , Fármacos Neuromusculares Despolarizantes/administración & dosificación , RocuronioRESUMEN
CONTEXT: Sugammadex has steroid-encapsulating effect. AIM: This study was undertaken to assess whether the clinical efficacy of sugammadex was altered by the administration of steroids. SETTING AND DESIGN: Sixty patients between 18 and 60 years of age with the American Society of Anesthesiologists I-IV and undergoing elective direct laryngoscopy/biopsy were included in this study. MATERIALS AND METHODS: Patients were assigned to two groups based on the intraoperative steroid use: those who received steroid (Group S) and who did not (Group C). After standard general anesthesia, patients were monitored with the train of four (TOF) monitoring. The preferred steroid and its dose, timing of steroid administration, and TOF value before and after sugammadex as well as the time to recovery (TOF of 0.9) were recorded. STATISTICAL ANALYSIS USED: SPSS software version 17.0 was used for statistical analysis. RESULTS: There is no statistically significant difference between groups in terms of age, gender, preoperative medication use, and TOF ratio just before administering sugammadex. The reached time to TOF 0.9 after sugammadex administration was significantly shorter in Group S than Group C (P < 0.05). A within-group comparison in Group S showed no difference in TOF ratio immediately before sugammadex as well as the dose of sugammadex in those who received prednisolone; time to TOF 0.9 was higher in prednisolone receivers as compared to dexamethasone receivers (P < 0.05). CONCLUSION: In patients receiving steroids, and particularly dexamethasone, an earlier reversal of neuromuscular block by sugammadex was found, in contrast with what one expect. Further studies are required to determine the cause of this effect which is probably due to a potential interaction between sugammadex and steroids.
Asunto(s)
Androstanoles/administración & dosificación , Dexametasona/farmacocinética , Bloqueo Neuromuscular/métodos , Fármacos Neuromusculares no Despolarizantes/administración & dosificación , Esteroides/administración & dosificación , gamma-Ciclodextrinas/administración & dosificación , Adolescente , Adulto , Anestesia General/métodos , Antieméticos/administración & dosificación , Antieméticos/farmacocinética , Dexametasona/administración & dosificación , Procedimientos Quirúrgicos Electivos/métodos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Monitoreo Neuromuscular , Estudios Prospectivos , Sugammadex , Factores de Tiempo , Adulto JovenRESUMEN
AIM: This prospectively-planned, randomized, double-blind and placebo-controlled study aims to evaluate the effect of 1200 mg gabapentin premedication on the incidence and severity of propofol and rocuronium injection pain. METHOD: One hundred patients, between 18-60 years of age and ASA I-II for elective surgery planned under general anaesthetic, were randomized and divided into two groups. Two hours before the operation, the patients were given either a placebo tablet (Group P, n = 50) or 1200 mg gabapentin tablet (Group G, n = 50). On the back of the non-dominant hand, a vein was opened using a 20 G cannula , 0.9% NaCl was begun and preoxygenation was provided. For anaesthesia induction, 1% propofol at 800 ml/hr infusion rate was administered for 20 s. Propofol injection pain was evaluated up to the 20th second and recorded using a scale between 0 and 3 developed by McCrirrick and HunteR The remaining propofol dose (2.5 mg/kg), 5 ml saline and 0.6 mg/kg rocuronium were injected in that order over 10 seconds and rocuronium injection pain response was evaluated with a four point scale. RESULTS: Pain after propofol infusion average score (degree ≥ 1) (Group G = 0.5; Group P = 1.0) and incidence (Group G = 46%; Group P = 68%); and average withdrawal movements response score linked to rocuronium injection pain (≥ 1 response) (Group G = 0.3; Group P = 1.2) and incidence (Group G = 20%; Group P = 80%) were detected to be significantly lower in the gabapentin group compared to the placebo group (p < 0.001). CONCLUSION: Premedication with 1200 mg gabapentin 2 hours before propofol and rocuronium injection reduced the incidence and severity of injection pain.